FindTrial
Sign In

AZD0022

DRUG2 trials

Sponsors

AstraZeneca AB, AstraZeneca

Conditions

Advanced Solid TumoursColorectal Cancer (CRC)Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal AdenocarcinomaNon-Small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)

Phase 1

A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation
TerminatedNCT06599502
AstraZenecaAdvanced Solid Tumours, Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC) +1
Start: 2024-10-18End: 2026-01-29Updated: 2026-03-18
A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination with Anti-cancer Agents in Participants with Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01)
CompletedCTIS2024-516699-14-00
AstraZeneca ABNon Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenocarcinoma
Start: 2025-04-23End: 2025-10-09Target: 126Updated: 2025-08-22

Related Papers

Abstract ND11: AZD0022: a potent, oral KRASG12D-selective inhibitor that drives robust pathway inhibition and anti-tumour activity in KRASG12D models
Cancer Research2025-05-223 citations
Abstract 841: The preclinical pharmacokinetics and pharmacodynamics of AZD0022: A potent, oral KRASG12D-selective agent exhibiting oral bioavailability and KRAS pathway suppression in the GP2D xenograft model
Cancer Research2025-04-212 citations